PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 TrialConstructive Type C Meeting Provides Potential Pathway to Accelerated ...
Progression-free survival (PFS) is now the dominant endpoint in cancer clinical trials, but simply prolonging time to progression without extending overall survival or quality of life does not justify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback